secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001822
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics reports Q4 net loss of $4.1M; files IND for CLD-201 solid tumor trial
--------------------------------------------------------------------------------

- Q4 2024 net loss $4.1M ($0.27/share) vs $8.2M loss ($0.23/share) in Q4 2023.
- Full year 2024 net loss $23.8M ($2.97/share) vs $29.2M ($17.33/share) in 2023.
- Cash and restricted cash $9.8M as of Dec 31, 2024, up from $2.1M as of Dec 31, 2023.
- IND filed in March 2025 for CLD-201 Phase 1 trial in solid tumors (breast, head&neck, sarcoma).
- CLD-101 Phase 1 trial for high-grade glioma started recruiting at Northwestern; 14th patient treated at City of Hope.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225001822/0001641172-25-001822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225001822/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer